… Twenty healthy male subjects were recruited in this study and all provided written informed
… Subjects were assessed to be healthy on the basis of screening examinations. Significant …

Objective: The objective of this study was to assess the safety, tolerability, pharmacokinetics,
and pharmacodynamics of selexipag, an orally available selective prostacyclin receptor …

… In this phase I study, selexipag was well tolerated in healthy male subjects receiving both
single oral doses up to 400 µg and multiple oral doses of twice-daily 600 µg (following up-…

… has shown that only if healthy subjects develop headache, it is … induce headache in healthy
subjects accompanied by dilatation … in healthy volunteers in a double blind crossover study. …

… to be related to the vasodilatory properties of prostacyclin receptor agonists. The more
pronounced reduction in blood pressure in patients compared with healthy subjects suggests that …

… , and selective prostacyclin receptor (IP) agonist is being … formulation of ralinepag in
healthy subjects. Blood samples … Eighty-two healthy subjects (single ascending dose (n = 32) …

… Patients were excluded if they had had clinically unstable right heart failure within the last 3
months (World Health … Data from 29 patients in the selexipag group and six patients in the …

… In summary, a single iv administration of selexipag in healthy subjects is safe and well-tolerated.
The results obtained in this study suggest that selexipag exhibits a first-pass effect and …

… SC infusion over 28 days of treprostinil to 14 healthy adults was 2.93 h [Citation49]. … A
phase I study of 64 healthy male subjects showed that selexipag was well tolerated up to a single …

… circulating volume and in patients with chronically reduced kidney … This indicates that
prostacyclin mediates an IP receptor–… infusion of prostacyclin 24 and iloprost 25 to healthy …